Xencor Inc (XNCR) Expected to Post Quarterly Sales of $60.05 Million
Analysts expect Xencor Inc (NASDAQ:XNCR) to report sales of $60.05 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Xencor’s earnings. The highest sales estimate is $126.25 million and the lowest is $13.90 million. The business is scheduled to report its next quarterly earnings results on Monday, May 6th.
On average, analysts expect that Xencor will report full year sales of $102.90 million for the current year, with estimates ranging from $59.10 million to $147.50 million. For the next fiscal year, analysts anticipate that the business will report sales of $82.02 million, with estimates ranging from $8.00 million to $124.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Xencor.
A number of research analysts have recently commented on the stock. Cantor Fitzgerald restated a “buy” rating and set a $40.00 price target on shares of Xencor in a research report on Tuesday, February 5th. Zacks Investment Research upgraded Xencor from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a report on Friday, December 14th. BidaskClub upgraded Xencor from a “hold” rating to a “buy” rating in a report on Tuesday, January 1st. Piper Jaffray Companies boosted their target price on Xencor to $56.00 and gave the stock an “overweight” rating in a report on Tuesday, February 26th. Finally, Berenberg Bank began coverage on Xencor in a report on Wednesday, March 27th. They set a “buy” rating and a $45.00 target price for the company. Two equities research analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $41.43.
In related news, major shareholder John S. Stafford III purchased 5,500 shares of Xencor stock in a transaction that occurred on Monday, March 25th. The shares were purchased at an average cost of $29.84 per share, with a total value of $164,120.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder John S. Stafford III purchased 38,300 shares of Xencor stock in a transaction that occurred on Friday, March 15th. The shares were bought at an average cost of $29.02 per share, for a total transaction of $1,111,466.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 46,900 shares of company stock worth $1,368,396 over the last three months. 4.70% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in XNCR. Equitec Specialists LLC grew its stake in Xencor by 6.1% during the 1st quarter. Equitec Specialists LLC now owns 10,417 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 600 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Xencor by 46.9% in the fourth quarter. Meeder Asset Management Inc. now owns 2,910 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 929 shares during the period. Chartwell Investment Partners LLC lifted its holdings in shares of Xencor by 3.2% in the fourth quarter. Chartwell Investment Partners LLC now owns 40,778 shares of the biopharmaceutical company’s stock valued at $1,475,000 after buying an additional 1,264 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Xencor by 5.4% in the third quarter. Wells Fargo & Company MN now owns 25,710 shares of the biopharmaceutical company’s stock valued at $1,002,000 after buying an additional 1,310 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Xencor by 8.8% in the fourth quarter. Legal & General Group Plc now owns 18,728 shares of the biopharmaceutical company’s stock valued at $678,000 after buying an additional 1,517 shares during the period. 84.71% of the stock is currently owned by hedge funds and other institutional investors.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Story: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.